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Regulation of Histone Acetylation and Transcription
by INHAT, a Human Cellular Complex Containing
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ylation of histone and nonhistone substrates (Bannister
and Kouzarides, 1996; Ogryzko et al., 1996; Yang et al.,
1996; Gu and Roeder, 1997). These properties, along
with the recent reports that the histone acetyltransferase
(HAT) activity of p300/CBP and PCAF are required for
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that histone acetylation has a fundamental biological†Harvard Microchemistry and Proteomics Facility
Harvard University role and suggest that this process might be regulated
(Puri et al., 1997; Korzus et al., 1998; Kraus et al., 1999).Cambridge, Massachusetts 02138
Indeed, coactivator–acetylase activity can be regu-
lated by interactions with cellular and viral regulatory
proteins, and by posttranslational modifications. TheSummary
ability of the adenoviral oncoprotein, E1A, to inhibit the
acetyltransferase activity of p300/CBP and PCAF estab-Acetylation of histones by p300/CBP and PCAF is con-
sidered to be a critical step in transcriptional regulation. lishes blocking of histone acetylation as a new mode of
RNA polymerase II transcriptional control (ChakravartiIn order to understand the role of cellular activities that
modulate histone acetylation and transcription, we have et al., 1999; Hamamori et al., 1999). Likewise, the HIV1
transactivator protein, TAT, inhibits the acetylase activi-purified and characterized a multiprotein cellular com-
plex that potently inhibits the histone acetyltransfer- ties of two nuclear HATs, Tip60, and TAFII250 (Weissman
et al., 1998; Creaven et al., 1999). Finally, the inhibition ofase activity of p300/CBP and PCAF. We have mapped
a novel acetyltransferase-inhibitory domain of this GCN5-HAT activity via phosphorylation by the Ku-DNA
dependent protein kinase complex and the stimulationINHAT (inhibitor of acetyltransferases) complex that
binds to histones and masks them from being acetyl- of the HAT activity of CBP and ATF-2 by phosphorylation
demonstrate a role for posttranslational modification astransferase substrates. Endogenous INHAT subunits,
which include the Set/TAF-Ib oncoprotein, associate a HAT-regulatory mechanism (Ait-Si-Ali et al., 1998; Bar-
lev et al., 1998; Kawasaki et al., 2000). Potential mecha-with chromatin in vivo and can block coactivator-
mediated transcription when transfected in cells. We nisms for blocking histone acetylation could conceptu-
ally involve direct binding and subsequent inhibition ofpropose that histone masking by INHAT plays a regula-
tory role in chromatin modification and serves as a the acetylases by regulatory proteins. Alternatively, the
regulatory proteins may bind to histones to occludenovel mechanism of transcriptional regulation.
them from serving as acetyltransferase substrates: a
property that we refer to as “histone masking”. AlthoughIntroduction
the latter possibility has never been documented in inhi-
bition of histone acetylation, it should be consideredNucleosomes, the building blocks of higher order chro-
matin structure, play important structural and regulatory as a potential cellular mechanism to directly regulate
histone acetylation and transcription.roles in the control of gene expression in eukaryotes. A
body of genetic and biochemical evidence link hyper- In the present study, we have biochemically purified
and molecularly characterized a novel human cellularacetylation of lysine residues of histone tails to tran-
scriptionally active chromatin domains (Grunstein, 1997; complex termed INHAT (inhibitor of acetyltransferases)
that inhibits the HAT activity of p300/CBP and PCAF byStruhl, 1998; Tyler and Kadonaga, 1999; Strahl and Allis,
2000). The mechanisms by which histone acetylation binding to their substrate, histones. Subunits of this
complex include the myeloid leukemia associated onco-alters gene expression profiles remain to be elucidated.
However, crystallographic analysis of the nucleosomal protein Set/TAF-Ib, and pp32, a member of a family
of nuclear phosphoproteins (von Lindern et al., 1992;particle containing core histones predicts that the N-ter-
minal tail of histone H4 has the ability to contact adjacent Adachi et al., 1994; Nagata et al., 1995; Chen et al.,
1996). We present both in vitro and in vivo evidencenucleosomes, suggesting acetylation or deacetylation
of histone tails may influence higher order chromatin implicating a role for this complex in the regulation of
histone acetylation and transcription. We propose thatstructure and hence gene expression (Luger et al., 1997).
p300/CBP and PCAF are transcriptional coactivators histone masking by INHAT may serve as a key event in
chromatin remodeling and transcriptional regulation.and are proposed to contribute to transcription by es-
tablishing direct interactions with transcription factors
such as nuclear hormone receptors and/or as part of Results
a coactivation complex (reviewed in Freedman, 1999;
Glass and Rosenfeld, 2000). Additionally, because of Identification and Purification of the Cellular
their intrinsic acetyltransferase activities, p300/CBP and HAT-Inhibitory Activity (INHAT)
PCAF further facilitate transcription by promoting acet- In order to identify a cellular activity that inhibits histone
acetylation, we analyzed the effect of addition of HeLa
cell nuclear extracts on p300 mediated histone acetyla-‡ To whom correspondence should be addressed (e-mail: debu@
pharm.med.upenn.edu). tion (Figures 1A and B). Preincubation of purified p300
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Figure 1. Identification and Purification of the INHAT Complex
(A) INHAT purification scheme is shown.
(B) Identification and purification of INHAT. p300 was incubated without (lane 4) or with HeLa cell nuclear extracts (lane 5), supernatant of
0%–65% ammonium sulfate precipitation (lane 6), and DEAE-sephacel chromatography pooled fractions (lane 7) prior to the addition of
histones. Positions of acetylated histones are shown (lanes 4–7). Samples of the active INHAT fractions were separated by SDS-PAGE, and
stained with Coomassie (lanes 1–3).
(C) The absorbance profile of Sephacryl S-200 gel filtration chromatography is shown in panel I. The INHAT activity of fractions (panel II,
phosphorimager) and their SDS-PAGE analysis (panel III, Coomassie) are shown.
(D) Reconstitution of the INHAT activity. Panel I shows Coomassie staining of each renatured subunit of INHAT; p31 (lane 1), p32 (lane 2),
p44 (lane 3), and p48 (lane 4). Renatured polypeptides were assayed individually and in combination for the INHAT activity as shown (panel
II, phosphorimager, lanes 3–9). Lanes 1, and 2 show histone acetylation by p300 in the absence or presence of HeLa cell nuclear extracts,
respectively, and lane 10 (CT) shows the HAT assay with a control gel slice.
with HeLa cell nuclear extracts significantly inhibited (Figures 1A and 1B, Coomassie). Following initial ammo-
nium sulfate fractionation (Figure 1B, lanes 2 and 6), thehistone acetylation (Figure 1B, phosphorimager, com-
pare lane 4 with lane 5). These results suggested the peak of the INHAT activity eluted at approximately 0.23
M KCl of a linear salt gradient of a DEAE sephacel col-putative existence of a cellular histone acetyltransfer-
ase–inhibitory activity, which we named INHAT (inhibitor umn (lanes 3 and 7). The INHAT activity was further
purified by Sephacryl S-200 gel filtration chromatogra-of acetyltransferases).
Using the above assay and a combination of ion ex- phy as a single peak with an approximate molecular
mass of 150 to 170 kDa (Figure 1C, panels I and II), which,change and gel filtration sizing chromatography, we pu-
rified the INHAT activity from HeLa cell nuclear extracts upon polyacrylamide gel analysis (panel III), revealed the
Histone Masking by INHAT
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Figure 2. Biochemical Properties of the
INHAT Complex
(A) Dose-dependent inhibition of histone acet-
ylation by the INHAT complex. HAT assays
were performed with increasing concentra-
tions (0–0.6 mM) of the INHAT complex. In lane
1, p300 was incubated with histones only. The
lower panel shows Coomassie staining of the
same gel. Positions of histone H3 and H4 are
shown.
(B) Determination of IC50. The radioactivity of
individual histone bands from (A) was deter-
mined from the phosphorimager and percent
activity remaining calculated using the value
of acetylation of histone H3 and H4 in the
absence of INHAT as 100%. The IC50 values
were calculated by determining the concen-
tration of INHAT needed for 50% inhibition of
histone H3 (upper panel) and H4 (lower panel)
acetylation by p300.
(C) INHAT inhibits acetylation of histones.
p300 (1 pmol) was preincubated without (2)
or with (1) 15 pmol of INHAT prior to the
addition of 500 ng of histone H3, H4, H2A, or
H2B as shown.
(D) Dose-dependent rescue of INHAT inhibi-
tion of histone H4 acetylation. p300 (1 pmol)
was preincubated with 3 pmol of INHAT (lane
2) and increasing amounts of histone H4; 100
ng (lane 2), 250 ng (lane 3), 500 ng (lane 4),
and 1 mg (lane 5). In lane 1, 100 ng of histones
were assayed without INHAT.
presence of 4 major polypeptides ranging in molecular tyltransferases acetylate core histones to varying de-
grees also, suggesting that both INHAT and acetylasesweights of 48 (p48), 44 (p44), 32 (p32), and 31(p31) kDa.
exhibit substrate preference which may be due to theirTo determine which polypeptide has the HAT-inhibi-
differential affinity for core histones (Figure 2C) (Schiltztory activity, each of them was separately eluted from
et al., 1999). No proteolytic degradation of histones ingel slices, denatured, renatured, and assayed alone or
the presence of INHAT was evident (Figure 2A, Coomas-in combination for INHAT activity (Figure 1D, panel I).
sie). Quantitative analyses of the data presented in Fig-While each polypeptide inhibited histone H3 and H4
ure 2A indicate relative IC50 values of 0.2 mM for H3 andacetylation to a varying degree (panel II, lanes 3 to 8),
0.12 mM for H4 (Figure 2B, upper and lower panels,maximal inhibition was observed when all 4 renatured
respectively). These IC50 values for the INHAT complexpolypeptides were combined (lane 9). Furthermore, we
are similar to those of two bisubstrate synthetic inhibi-note that consistent with the results of Figure 1C, ace-
tors of p300 and PCAF and also demonstrate that thetylation of histone H4 was predominantly inhibited. A
INHAT complex has 20- to 50-fold higher HAT-inhibitorycontrol gel slice showed no inhibitory activity (lane 10).
activity than that of E1A (Chakravarti et al., 1999; LauFrom these results, we conclude we have purified a
et al., 2000).cellular complex termed INHAT whose individual sub-
To further characterize the nature of INHAT-mediatedunits can inhibit p300-mediated histone acetylation.
inhibition of histone acetylation, we performed a rescue
experiment. If the hypothesis that INHAT functions by
Characterization of the INHAT Complex targeting the substrate leaving the acetylase free were
To investigate the mechanism and nature of INHAT inhi- correct, one would expect that addition of excess sub-
bition, we performed a dose dependence study. Incuba- strate (histones) would relieve INHAT-mediated inhibi-
tion of histones with increasing concentrations of INHAT tion. At predetermined concentrations of histones and
resulted in the progressive inhibition of histone acetyla- p300, INHAT completely inhibited histone H4 acetylation
tion in a manner where acetylation of histone H4 was (Figure 2D, compare lane 1 with lane 2). Addition of
more sensitive to inhibition than that of H3 at lower increasing concentrations of histone H4 relieved the
concentrations of INHAT (Figure 2A, phosphorimager, INHAT-mediated inhibition of histone acetylation in a
compare lane 1 with lanes 2–4). At higher concentra- dose-dependent manner, suggesting INHAT may medi-
tions, however, INHAT inhibited acetylation of all his- ate inhibition by targeting histones (Figure 2D, compare
tones (Figure 2A, lanes 5–7, and Figure 2C). These re- lane 2 with lanes 3–5).
sults are in agreement with those of Figures 1C and 1D p300, CBP, and PCAF are known to acetylate core
and suggest that among histones, histone H4 may serve histones and nucleosomes with varying degrees of
as a predominant target for INHAT-mediated inhibition. histone specificity (Bannister and Kouzarides, 1996;
Ogryzko et al., 1996; Yang et al., 1996; Schiltz et al.,Interestingly, in vitro studies indicated that histone ace-
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see also Figure 1B). Finally, the addition of the INHAT
complex subsequent to the HAT assay had no effect on
the status of histone acetylation (Figure 3F, compare
lane 1 with lane 2, and lane 3 with lane 4). These results
suggest that the INHAT complex may not function as
an alternate substrate or at a postacetylation stage but
rather has a direct role in inhibiting acetylation of his-
tones and nucleosomes.
Set/TAF-Ib, TAF-Ia, and pp32 are Subunits
of the INHAT Complex
To identify the subunits of the INHAT complex, peptide
sequences of p48, p44, p32, and p31 were obtained
utilizing ion trap tandem mass spectrometry. These
sequencing data identified p48 as the human template
activating factor-Ia (TAF-Ia), and p44 as the human
myeloid leukemia associated oncoprotein Set, which is
also known as the template activating factor-Ib (Set/
TAF-Ib) (Experimental Procedures, LC/MS/MS peptide
sequencing) (von Lindern et al., 1992; Adachi et al., 1994;
Nagata et al., 1995). Except for the subtype-specific N
terminus, Set/TAF-Ib and TAF-Ia are identical (Nagata
et al., 1995). Finally, peptide sequencing results demon-
strated that p31 is derived from p32 and that they are
Figure 3. INHAT Blocks Nucleosome Acetylation identical to pp32, a member of the family of leucine rich
(A) INHAT blocks PCAF-mediated histone acetylation. PCAF was acidic nuclear phosphoproteins (Experimental Proce-
incubated without (lane 1) or with INHAT (lane 2) prior to the addition dures, LC/MS/MS Peptide Sequencing) (Chen et al.,
of core histones. 1996).
(B) INHAT blocks nucleosome acetylation. PCAF (lanes 1 and 2) and
To validate further the identity of the components ofp300 (lanes 3 and 4) were separately incubated without (lanes 1 and
the INHAT complex, immunoblot analyses of the Sepha-3) or with INHAT (lanes 2 and 4), prior to the addition of nucleosomes.
(C and D) INHAT blocks histone acetylation by the isolated HAT cryl S-200 gel filtration fractions (see Figure 1C) were
domains of p300 (C) and CBP (D). p300 (964–1810) (1 pmol) or GST- performed (Figure 4A, Western). Polyclonal antibodies
CBP (1196–1718) (10 pmol) was preincubated without (lanes 1) or that recognize both TAF-Ia and Set/TAF-Ib reacted
with (lanes 2) 15 pmol of INHAT prior to the addition of histones. strongly with p48 and p44 (Panel II) (Nagata et al., 1998).
(E) INHAT subunits are not acetylated. p300 (lanes 1 and 2) or PCAF
Likewise, polyclonal anti-human pp32 antibodies recog-(lanes 3 and 4) was incubated with either histones (lanes 1 and 3)
nized both p32 and p31 (Panel III) (Chen et al., 1996).or INHAT (lanes 2 and 4).
(F) INHAT does not function at a post-acetylation stage. Following To demonstrate that TAF-Ia, Set/TAF-Ib, and pp32 are
incubation of p300 (lanes 1 and 2) and PCAF (lanes 3 and 4) with present as a complex in an active INHAT preparation, we
core histones, and 14[C]-acetyl CoA for 10 min, purified INHAT com- performed co-immunoprecipitation and in vitro binding
plex was added (lanes 2 and 4), and reaction mixtures incubated experiments. Incubation of the INHAT-DEAE sephacel
for an additional 10 min at 308C.
pooled fraction (lane L of Figure 4A) with anti-pp32 anti-
bodies led to the co-immunoprecipitation of TAF-Ia and
Set/TAF-Ib suggesting the existence of a tripartite pp32-1999). We therefore examined in Figure 3 the effects
TAF-Ia-Set/TAF-Ib endogenous complex (Figure 4B,of INHAT on acetylation of histones and nucleosomes.
lane 2). Additionally, both TAF-Ia and Set/TAF-Ib areConsistent with previous observations, PCAF acetylated
retained on a GST-pp32- glutathione sepharose affinitycore histones H3, H4, and predominantly histone H3 of
matrix indicating that these proteins can also form com-nucleosomes (Figures 3A and 3B, respectively, lane 1)
plexes in vitro (Figure 4C, lane 3). Finally, consistent(Yang et al., 1996). INHAT strongly inhibited PCAF medi-
with the published results that TAF-Ia and Set/TAF-Ibated acetylation of histones and nucleosomes (Figures
inhibit protein phosphatase 2A (PP2A), we also observed3A and B, respectively; compare lane 1 with lane 2). In
strong PP2A inhibitory activity of the INHAT complexaddition, INHAT also blocked acetylation of histones by
(not shown) (Li et al., 1996; Saito et al., 1999). Together,ACTR (not shown) (Chen et al., 1997). The INHAT com-
these results are consistent with Set/TAF-Ib, TAF-Ia,plex similarly inhibited p300-mediated acetylation of
and pp32 being subunits of the INHAT complex.nucleosomes (Figure 3B, compare lane 3 with lane 4).
Finally, INHAT blocked acetylation of histones by the
isolated HAT domain of p300 and CBP (Figures 3C and Mapping of the INHAT Domain
To confirm that INHAT activity is an intrinsic property3D, respectively). These results suggest that INHAT
blocks acetylation of histones and nucleosomes. We of the identified subunits and not mediated by an un-
identified nonspecific component of the INHAT com-also determined whether INHAT functions as an alter-
nate substrate of acetylases or mediates its effect at a plex, we assessed the effects of recombinant INHAT
subunits in HAT assays. Consistent with the results ob-postacetylation stage. Neither p300 nor PCAF ace-
tylated any component of the INHAT complex under the tained with biochemically purified INHAT complex (Fig-
ure 1), Figure 5A shows that individually purified, recom-experimental conditions used (Figure 3E, lanes 2 and 4,
Histone Masking by INHAT
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Figure 4. Identification of the INHAT Subunits
(A) Immunochemical identification of INHAT subunits. Sephacryl S-200 gel filtration fractions (fraction # 14 to 18, see Figure 1C) and DEAE-
Sephacel pooled fraction (lane L) with INHAT activity (panel I, Coomassie) were analyzed in immunoblots using antibodies recognizing TAF-
Ia, Set/TAF-Ib (panel II, Western), and pp32 (panel III, Western).
(B) Complex formation by TAF-Ia, Set/TAF-Ib, and pp32. DEAE sephacel pooled fraction (input, lane 1) was incubated with anti-pp32 antibodies
and coimmunoprecipitated proteins were detected in an immunoblot using a mixture of anti TAF-Ia, and Set/TAF-Ib antibodies (lane 2).
(C) pp32 binds to TAF-Ia, and Set/TAF-Ib in vitro. Radiolabeled TAF-Ia, and Set/TAF-Ib (lane 1) were incubated with GST (lane 2) or GST-
pp32 (lane 3) bound to glutathione sepharose beads. WB Abs, Western (immuno) blot antibodies; IP Abs, immunoprecipitation antibodies.
binant INHAT subunits Set/TAF-Ib (construct 1), TAF-Ia dose-dependent manner (Figure 5D). Surprisingly, pep-
tide 3, which is derived from Set/TAF-Ib and also rich(construct 2), and pp32 (construct 3) inhibited p300-
mediated acetylation of histones. These results further in acidic amino acids failed to inhibit histone acetylation
at all concentrations tested thereby serving as an inter-validate that the HAT-inhibitory property of INHAT com-
plex maps to its identified subunits. nal negative control (Figure 5D). These results suggest
that Set/TAF-Ib-mediated HAT-inhibition is not due toSince recombinant Set/TAF-Ib inhibits histone ace-
tylation, Set/TAF-Ib deletion mutants were examined to a nonspecific inhibitory effect of any acidic region but
rather maps to a specific domain at the C termini of Set/broadly map the HAT-inhibitory domain (Figure 5B). De-
letion of the subtype specific N-terminal sequence (con- TAF-Ib (amino acids 223–264) and TAF-Ia (amino acids
236–278).struct 4) had no effect on HAT-inhibition (indicated as
111). In contrast, a Set/TAF-Ib mutant, lacking the en-
tire C-terminal acidic tail (construct 6) was completely INHAT Directly Binds to Histones In Vitro
and Associates with Chromatin In Vivoinactive (indicated as none). Similar results were also
obtained with TAF-Ia proteins (not shown). These results There are several possibilities by which the INHAT com-
plex might inhibit acetylase activity. INHAT may bind toindicate that the major HAT-inhibitory activity maps to
the carboxyl termini of Set/TAF-Ib and TAF-Ia. To map the acetylases blocking their activity. However, results
from Figure 2D indicate that INHAT might directly asso-the HAT inhibitory domain further, additional Set/TAF-
Ib mutants were generated (constructs 7 to 9). While Set/ ciate with histones. To test the above possibilities, in
vitro immunoprecipitation experiments utilizing radiola-TAF-Ib:100–277 (construct 7) showed robust activity,
progressive decreases in HAT inhibitory activity were beled INHAT subunits and histones were carried out. In
vitro labeled TAF-Ia, Set/TAF-Ib, and pp32 (Figure 6A,clearly evident when Set/TAF-Ib:100–250 and Set/TAF-
Ib:120–225 mutants were examined (constructs 8 and lanes 1 and 4) were very efficiently immunoprecipitated
with anti-histone antibodies, suggesting a direct interac-9, respectively). Set/TAF-IbDC3 (aa 1 to 225) showed
partial HAT inhibitory activity (construct 5), suggesting tion between subunits of INHAT and histones (Figure
6A, lanes 2 and 5) (Okuwaki and Nagata, 1998). To corre-the possible existence of a minor HAT inhibitory domain
at the amino terminus of the protein, which remains to late that histone binding is necessary for INHAT-medi-
ated inhibition, we tested two selected mutants of Set/be investigated. Nonetheless, these results localize the
major HAT-inhibitory activity to the C-terminal acidic TAF-Ib for their ability to bind histones. GST fusion of
Set/TAF-Ib: 100–277, which very efficiently inhibited his-tail spanning the amino acids 225 to 277 of Set/TAF-Ib
(termed INHAT domain). tone acetylation (Figure 5B), also bound histones as
determined by immunoprecipitation-Western (immuno)For finer mapping, peptides spanning the glutamic
and aspartic acid (E/D) rich INHAT domain were synthe- blot analysis (Figure 6B, lane 2). In contrast, Set/TAF-
Ib: 120–225 that did not inhibit histone acetylation (Fig-sized and examined (Figures 5C and 5D). Peptides 1, 2,
and 4 strongly inhibited acetylation of histones H4 in a ure 5B), also showed no association with histones (Fig-
Cell
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Figure 5. Recombinant Set/TAF-Ib, TAF-Ia, and pp32 Inhibit Histone Acetylation and Mapping of the INHAT Domain
(A) Recombinant INHAT subunits block histone acetylation. Unique N-terminal regions of Set/TAF-Ib and TAF-Ia are shown as striped boxes.
p300 was incubated with recombinant Set/TAF-Ib (construct 1), TAF-Ia (construct 2), or pp32 (construct 3).
(B) Mapping of the INHAT domain. p300 was incubated with Set/TAF-Ib mutants as indicated (constructs 4 to 9). The INHAT activity is
designated as 111 (high activity), 1 (little activity, 10%–20% of the wild type), or none (no activity).
(C) Sequences of the synthesized INHAT peptides representing set/TAF-Ib and TAF-Ia C-terminal amino acids are indicated as peptides #1,
#2, #3, and #4.
(D) Functional analysis of INHAT peptides. Different concentrations of peptides #1, #2, #3, and #4 were assayed for their INHAT activities as
indicated. Percent activity remaining was calculated and plotted for each assay point using the value of uninhibited p300 (without INHAT) as
100%.
ure 6B, lane 5). These results provide a correlation be- to acetylases, interaction assays utilizing radiolabeled
INHAT subunits and p300 or PCAF were also carried out.tween histone binding and INHAT domain mediated
inhibition of acetylation by Set/TAF-Ib (Figure 6B, com- In contrast to the strong interactions between INHAT
subunits and histones, no interaction between INHATpare lane 2 with lane 5).
To determine whether INHAT functions by binding and either p300 or PCAF was observed (Figure 6C, lanes
Histone Masking by INHAT
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Figure 6. Association of INHAT and Histones In Vitro and on Chromatin In Vivo
(A) INHAT subunits bind to histones. In vitro labeled Set/TAF-Ib and TAF-Ia (lane 1), and pp32 (lane 4) were incubated with (lanes 2 and 5) or
without (lanes 3 and 6) histones and immunoprecipitated with anti-histone antibodies. Lanes 1 and 4 represent 10% of the input.
(B) Correlation between histone binding and acetylation inhibition. GST-Set/TAF-Ib:100–277 (lane 1) and 120–225 (lane 4) were separately
incubated with (lanes 2 and 5) or without (lanes 3 and 6) histones and immunoprecipitated with anti-histone antibodies. Bound proteins were
detected by immunoblot analysis using anti-GST antibodies. Lanes 1 and 4 indicate 15% of the input.
(C) INHAT does not interact with acetylases. In vitro radiolabeled INHAT subunits (lane 1, 10% of the input) were incubated with purified Flag-
p300 (lane 2) or Flag-PCAF (lane 3) bound to anti-Flag antibody affinity beads. In lane 4, radiolabeled INHAT subunits were incubated with
anti-Flag antibody affinity beads only. In lanes 5 and 6, radiolabeled RAR was incubated with Flag-p300 and Flag-PCAF, respectively, in the
presence of ATRA.
(D) INHAT subunits associate with histones on chromatin in vivo. Formaldehyde cross-linked HeLa cell chromatin fraction (Input, 10% of the
material used for immunoprecipitation) was immunoprecipitated with anti-histone (a-histones) or control antibodies (CT). Following elution
and reversal of cross-linking, bound proteins were detected in immunoblots using anti INHAT subunit antibodies as indicated.
(E and F) Site preference of inhibition of acetylation. Histones (E) or nucleosomes (F) were separately incubated with PCAF in the presence
(1) or absence (2) of INHAT. Assay products were detected in immunoblots using antibodies specific for indicated acetylated lysine residues
of histone H4 and H3. In (F), phosphorimager analysis of the immunoblotted membrane is also shown.
2 and 3, respectively). However, as expected, the same protein–protein cross-links in cells, we isolated soluble
chromatin from formaldehyde cross-linked, sonicatedpreparations of p300 and PCAF interacted with the reti-
noic acid receptor (RAR) in the presence of all trans HeLa cells and performed chromatin immunoprecipita-
tion assays (ChIP) using anti- histone or control antibod-retinoic acid (lanes 5 and 6, respectively). These results
are consistent with those of Figure 2D, and strengthen ies (Figure 6D) (Jackson, 1978; Chen et al., 1999). INHAT
subunits were detected only in the chromatin fractionthe hypothesis that INHAT binds to histones and possi-
bly masks them from serving as acetylase substrates. immunoprecipitated with anti-histone antibodies and
not with a control antibody (Figure 6D, IP, compare a-his-Since histones are an integral part of chromatin and
the observation that INHAT binds to histones prompted tones and CT lanes). The amounts of INHAT subunits
immunoprecipitated were qualitatively proportional tous to investigate whether endogenous INHAT might as-
sociate with histones on chromatin in vivo. Because their relative concentrations in HeLa cells (Figure 6D,
Input). These results indicate an in vivo association be-formaldehyde can produce reversible DNA-protein, and
Cell
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tween endogenous INHAT subunits and histones on ures 7C and 7D, respectively). Consistent with its potent
HAT inhibition and histone binding properties, Set/TAF-chromatin.
Several studies have linked acetylation of lysine 8 of Ib:100–277 inhibited RAR activity (Figure 7C, lane 7).
More importantly, Set/TAF-Ib:120–225 lacking the HAT-histone H4 and lysine 14 of histone H3 to transcriptional
activation (Strahl and Allis, 2000). To determine if the inhibitory INHAT domain and histone binding activity
failed to inhibit RAR mediated gene activation (Figureacetylation of these lysine(s) is inhibited by INHAT, im-
munoblot analyses using antibodies specific for individ- 7C, lane 5). Additional Set/TAF-Ib mutants behaved in
these cell-based transcription assays (Figures 7C andually acetylated lysine (K) of histones were performed.
The INHAT complex potently inhibited acetylation of 7D) in a manner consistent with their HAT inhibitory
properties (Figure 5B). These results are consistent withlysine 8 of histone H4 and lysine 14 of histone H3 by PCAF
(Figures 6E and 6F, panels a-AcH4 K8 and a-AcH3 K14, the in vitro analysis of INHAT and its derivatives and
correlate with a role for INHAT in regulating acetylasecompare 2 and 1 INHAT lanes). In contrast, INHAT-
mediated inhibition of acetylation of lysine 5, 12, and dependent transcription and RAR signaling.
16 of histone H4 was moderate to marginal. Note that
acetylation of these sites was low even in the absence Discussion
of the INHAT complex. Together, these results reveal
that INHAT binds to histones in vitro, endogenous INHAT Properties of the INHAT Complex
associates with histones on chromatin in vivo, and sug- This work provides both biochemical and functional
gest that INHAT functions by masking the accessibility characterizations of a novel human complex termed
of lysines of histones to the acetylases. INHAT that strongly inhibits HAT/coactivator-mediated
acetylation of core histones and nucleosomes. Based
on our results we propose that INHAT functions by bind-INHAT Blocks Retinoic Acid Receptor Signaling
ing to histones and occluding them from serving asand HAT-Dependent Transcription
acetylase substrates: a property that we refer to as his-Several biochemical and cell-based studies have sug-
tone masking. The functional relevance of this acetylasegested a role for the HAT activity of coactivators in
inhibition by the INHAT complex comes from the demon-nuclear hormone receptor (NHR) signaling (Perlmann
stration that RAR signaling and CBP-HAT dependentand Evans, 1997; Korzus et al., 1998; Kraus et al., 1999).
transcriptional activation are severely inhibited by theWe therefore utilized coactivator-acetylase-dependent
introduction of exogenous INHAT in intact mammalianretinoic acid receptor (RAR)-mediated NHR signaling
cells and that an INHAT mutant defective in HAT inhibi-as a model “specific target” for the analysis of INHAT
tion is also impaired in histone binding and in blockingfunction in living mammalian cells. As previously re-
RAR signaling. Additionally, consistent with the hypoth-ported, a Gal4-RAR fusion activated the reporter gene
esis that INHAT functions by targeting histones, wetranscription in a ligand (all trans retinoic acid)-depen-
show that endogenous INHAT associates with histonesdent manner (Figure 7A, lane 1). This ligand-dependent
on chromatin in vivo. Given that HATs recognize a broadRAR signaling was strongly inhibited in a dose depen-
range of substrates, it is possible that additional INHATdent manner by the introduction of exogenous TAF-Ia
targets may exist. While the reason for INHAT subunits(lanes 2–4), Set /TAF-Ib (lanes 5–7), pp32 (lanes 8–10),
with apparently similar or overlapping activity formingor all of the INHAT subunits (lanes 11–12). These results
a complex is not clear at present, it is, however, interest-are consistent with the biochemical properties of INHAT
ing to note that their target acetylases, including p300,and suggest a role for INHAT in regulating acetylase
CBP, and PCAF with overlapping HAT activity, also formdependent NHR-mediated transcriptional signaling.
a multimeric acetylase complex (Chen et al., 1997;Since INHAT subunits block CBP-HAT activity in vitro
Schiltz et al., 1999). Finally, the predominant inhibition(Figure 3D), and acetylase dependent NHR signaling in
of acetylation of histone H4 and particularly of lysineintact cells (Figure 7A), we tested whether transcrip-
residue 8 of H4, by the INHAT complex is striking sincetional activation by a Gal4-CBP fusion encompassing
lysines 8 of histone H4 is preferentially acetylated duringthe HAT domain would be similarly inhibited by transient
transcriptional activation (Strahl and Allis, 2000).transfection of INHAT in intact cells. In agreement with
Set/TAF-Ib and TAF-Ia are predominantly localized ina previous report, a GAL4-DNA- binding domain fusion
the nucleus. They bind histones, show chromatin re-of CBP (1092–2002) activated transcription in a HAT-
modeling activity, and play a role in adenoviral DNAdependent manner (Figure 7B, lane 1) (Martinez-Balbas
replication (Adachi et al., 1994; Nagata et al., 1998; Oku-et al., 1998). This CBP-HAT-mediated transcriptional ac-
waki and Nagata, 1998). pp32 is a member of a familytivation was severely blocked when TAF-Ia (lanes 2–3),
of leucine-rich acidic nuclear proteins (Chen et al., 1996;Set/TAF-Ib (lanes 4–5), pp32 (lanes 6–7), or all the sub-
Kadkol et al., 1999). Given that very little was knownunits of INHAT (lanes 8–10) were introduced. These re-
about the transcriptional regulatory roles of the INHATsults are consistent with a role for INHAT in regulating
subunits, our results suggest potential roles of INHATHAT-dependent transcription.
subunits in chromatin remodeling and transcriptionalBiochemical analysis of Set/TAF-Ib mutants demon-
regulation.strates a correlation between histone binding and HAT
inhibition by the INHAT domain (Figures 5 and 6). There-
fore, to establish a link between INHAT-mediated HAT Molecular Basis of INHAT Function
Previous studies implicated that two opposing enzy-inhibition and transcriptional regulation, we analyzed
the effects of selected mutants of Set/TAF-Ib in RAR matic activities histone acetyltransferases (HATs) and
histone deacetylases (HDACs) promote transcriptionalsignaling and CBP-HAT dependent transcription (Fig-
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Figure 7. INHAT Blocks Retinoic Acid Re-
ceptor Signaling and HAT-Dependent Tran-
scriptional Activation
(A) Ligand-dependent RAR signaling is inhib-
ited by INHAT. CV-1 cells were transiently
transfected with the reporter construct
pMH100-TK-Luc, CMX-Gal4RAR (lane 1), and
increasing concentrations of indicated INHAT
plasmids (lanes 2–12).
(B) HAT-dependent transcriptional activation
by CBP is inhibited by INHAT. CV-1 cells were
transfected with the reporter, Gal4CBP (1092–
2002) (lane 1), and increasing concentrations
of INHAT plasmids as indicated (lanes 2–10).
(C and D) Set/TAF-Ib mutants defective in
HAT inhibition also fail to inhibit RAR (C) and
CBP (D) function. CV-1 cells were transfected
with the reporter, indicated Set/TAF-Ib deriv-
atives, and either Gal4RAR (C) or Gal4CBP
(1092–2002) (D). Percent Gal4RAR (A and C)
or Gal4CBP (B and D) activity remaining was
calculated using the value of the luciferase
reporter activity in the presence of Gal4RAR
and hormone, ATRA (lane 1 of A and C), or
Gal4CBP alone as 100% (lane 1 of B and D).
(E) Proposed model of INHAT function. We
propose INHAT binds to histones and masks
accessibility of lysines of histone tails to co-
activators/acetylases. INHAT and the hypo-
thetical IDAC complexes may therefore rep-
resent new routes for regulating chromatin
modification and gene expression (see Dis-
cussion for details).
activation and repression, respectively, by controlling masking activity of INHAT, therefore, may be necessary
to counterbalance the HAT stimulatory effect of otherthe level of histone acetylation (Figure 7E) (Wolffe, 1996;
Struhl, 1998). Therefore, it is conceivable that the pro- histone binding proteins, thereby providing a novel way
to directly regulate histone acetylation and transcription.cess leading to histone acetylation may be directly regu-
lated. This direct regulation could be achieved, in part, The proposed model also raises the question of whether
the INHAT complex or a different histone masking com-by association of histones with regulatory proteins; for
example, histone binding proteins that may function ei- plex (termed IDAC: inhibitor of deacetylases) is neces-
sary for inhibition of histone deacetylation (Figure 7E).ther by inhibiting or enhancing the access of histones to
the acetylases. Indeed, the activities of the mammalian The isolation and characterization of INHAT should allow
future studies on the in vivo role of histone maskingHat1 and CBP acetyltransferases are enhanced by
RbAp46 and RbAp48, respectively (Verreault et al., 1998; activities in chromatin remodeling and gene regulation.
In the light of the ability of the INHAT complex toZhang et al., 2000). It is proposed that the histone bind-
ing proteins RbAp46 and RbAp48 stimulate HAT activity associate with chromatin and to modulate the acetylase
activity of coactivators and hence transcription, oneand transcription, possibly by enhancing access of his-
tones to acetyltransferases (Zhang et al., 2000). Based might expect that the activity of the INHAT complex and
its targeting to chromatin would be regulated. The levelson our results, we postulate that INHAT represents a
novel class of HAT inhibitory histone binding complex of TAF-I proteins and pp32 are regulated in a tissue-
and cell-type-specific manner (Walensky et al., 1993;that functions as a direct regulator of the histone acet-
ylation/transcriptional activation pathway mediated by Nagata et al., 1998). In this regard, we also note that
Set/TAF-Ib and pp32 are phosphorylated in vivo andhistone acetyltransferases (Figure 7E). This histone
Cell
128
SSK167, 175SGKDLTKR182, 182RSSQTQNK189. p44 (Set/TAF-Ib/gi 171that they have potent protein phosphatase 2A (PP2A)
1383): 11KELNSNHDGADETSEK26, 27EQQEAIEHIDEVQNEIDR44, 45LNEQinhibitory activity (Kellogg et al., 1995; Li et al., 1996;
ASEEILKVEQK59, 65QPFFQK70, 71RSELIAK77, 110VEVTEFEDIK119, 120SGSaito et al., 1999). The regulatory roles, if any, of re-
YRIDFYFDENPYFENK137, 142EFHLNESGDPSSK154. p32/p31 (pp32/gi
stricted expression and/or posttranslational modifica- 5453880/U73477): 14TPSDVKELVLDNSR28, 34LEGLTDEFEELEFLSTIN
tion of INHAT subunits in modulation and targeting of VGLTSIANLPK62, 68KLELSDNR75, 76VSGGLEVLAEK86 (in p31), 87CPN
LTHLNLSGNK99, 100IKDLSTIEPLKKLENLK116, 117SLDLFNCEVTNLNDYthe INHAT activity remain to be investigated.
RENVFK137, 138LLPQLTYLDGYDRDDK153, 238KREPEDEGEDDD249. Ital-In conclusion, our results provide in vitro and in vivo
icized sequences represent peptides specific for either p48 or p44.evidence for the existence of a novel complex that can
regulate both histone acetylation and transcription. The
observations that Set/TAF-Ib is associated with leuke- HAT Assay
mia and is a component of INHAT suggest that the com- While purified histones were obtained commercially (Roche Molecu-
lar Biochemicals), nucleosomes were prepared as described (Chak-plex may have a fundamental cellular function. Our find-
ravarti et al., 1999). HAT assays were performed in the presence ofings also imply that altered histone acetylation may
10 mM sodium butyrate as described (Chakravarti et al., 1999).serve as a plausible mechanism by which the oncogenic
Unless otherwise indicated, for INHAT-mediated HAT inhibition
Set/TAF-Ib translocations might contribute to neoplas- assay, approximately 15 pmol of purified INHAT was preincubated
tic progression. Identification of this novel cellular HAT- for 5 min at 48C with approximately 1 pmol of p300, or PCAF before
inhibitor complex establishes a paradigm for identifying the addition of 500 ng–1 mg (25–50 pmol) of histones and 14[C]-acetyl
CoA (50 mCi/ml, 1000 pmol/ml, Sigma). When nucleosomes (2 mg)additional cellular regulators of histone and transcription
were used, 2–5 pmol of p300 and PCAF were used and incubationfactor– modifying enzymes and should facilitate future
was continued for 30 min. Reaction products were separated bystudies in chromatin modification and gene regulation.
SDS-PAGE and analyzed by phosphorimager.
Experimental Procedures
Reconstitution of INHAT Activity
Plasmids and Proteins Following SDS-PAGE of purified protein fractions, gel slices repre-
For bacterial and eukaryotic expression constructs of INHAT sub- senting different subunits of INHAT were excised, eluted, and rena-
units, the appropriate PCR-amplified fragments were cloned into tured as described (Baeuerle and Baltimore, 1988). Renatured pro-
pGEX 2TK and CMX-PL1 vectors, respectively. Gal4-CBP (1092– teins were utilized in the HAT-inhibition assays as described under
2002) was generated by cloning the appropriate PCR amplified frag- “HAT Assay”.
ment into CMXGal4-N vector. Sequences of all constructs sur-
rounding the cloning sites were verified by automated sequencing.
Recombinant proteins were expressed in BL 21 (DE3) E. coli cells Immunoblot Analysis and Coimmunoprecipitation of INHAT
(Novagen), purified using glutathione beads (Amersham-Pharmacia), For immunoblot analysis, protein fractions from gel filtration chro-
and cleaved by thrombin. Purification of baculovirus-expressed Flag- matography were separated by SDS-PAGE, transferred onto mem-
tagged p300, its derivative, and PCAF was carried out as described brane, and incubated with the indicated primary antibodies. For
(Chakravarti et al., 1999). For the purification of His-tagged Set / immunoprecipitation, DEAE sephacel pooled fraction with INHAT
TAF-Ib, TAF-Ia, and their derivatives (gifts of K. Nagata), Ni-NTA activity was incubated with anti-pp32 antibodies and protein A-aga-
resin (Qiagen) was used (Nagata et al., 1995). rose beads (Gibco-BRL) (Chen et al., 1996). The immunoprecipitate
was washed extensively, bound proteins separated by SDS-PAGE,
Purification of the INHAT Complex transferred onto membrane, and incubated with a mixture of mono-
HeLa cells were suspended in 10 mM Tris-HCl (pH 8.0), 10 mM KCl, clonal anti TAF-Ia and Set/TAF-Ib antibodies (Nagata et al., 1998).
1.5 mM MgCl2, 0.5 mM DTT, 0.2 mM EDTA, and a cocktail of protease The blots were probed with alkaline phosphatase-conjugated anti-
inhibitors (suspension buffer), and lysed by passing through a 23G rabbit or anti-mouse secondary antibodies (BioRad).
needle. After centrifugation, the nuclear pellet was resuspended in
suspension buffer containing 420 mM NaCl, and 25% glycerol, and
incubated at 48C for 30 min. Following centrifugation, the superna- In Vitro Immunoprecipitation and Interaction Assays
tant was dialyzed (nuclear extract). All purification steps were per- In vitro, 35[S]methionine-labeled TAF-Ia, Set /TAF-Ib, and pp32 were
formed at 48C in buffers containing a cocktail of protease inhibitors. synthesized using the CMX plasmids in a coupled transcription–
Approximately, 80 ml of HeLa cell nuclear extracts (10 mg/ml) were translation system (TNT, Promega), and incubated with histones for
fractionated with ammonium sulfate (0%–65% saturation) and the 30 min at room temperature in buffer containing 150 mM KCl, 20
dialyzed supernatant was applied onto a DEAE-Sephacel (Amer- mM Tris-HCl (pH 7.6), 5 mM MgCl2, 1 mM DTT, and 10 mg/ml BSA.
sham-Pharmacia) column and eluted with a linear gradient (100 to The complex was immunoprecipitated using anti-histones, MAB
700 mM KCl) of buffer A containing 20 mM Tris-HCl (pH 7.6), 100 3422 antibodies (Chemicon International), and protein A agarose.
mM KCl, 0.1 mM EDTA, and 10% glycerol. Fractions with INHAT For GST pull-down assays, in vitro labeled TAF-Ia and Set/TAF-Ib
activity were pooled. The concentrated pool from DEAE-Sephacel were incubated with glutathione sepharose bound GST or GST-
was applied onto a Sephacryl S-200 (Amersham-Pharmacia) gel pp32. Beads were washed extensively and bound proteins sepa-
filtration column and eluted with buffer A. rated by SDS-PAGE and analyzed by phosphorimager.
For GST-Set/TAF-Ib:100–277 and 120–225 mutant proteins and
histone interaction assays, Set/TAF-Ib mutant proteins were incu-LC/MS/MS Peptide Sequencing
INHAT subunits were separated by SDS-PAGE. Excised bands were bated with or without histones and immunoprecipitated by incuba-
tion with anti-histone antibodies and protein A agarose beads.subjected to in-gel tryptic digestion followed by peptide sequencing by
microcapillary reverse-phase HPLC nano-electrospray tandem mass Bound proteins were analyzed in immunoblots using anti-GST anti-
bodies (Santa Cruz).spectrometry (mLC/MS/MS) on a Finnigan LCQ DECA quadruple ion
trap mass spectrometer. Interpretation of the resulting MS/MS spectra For p300 and PCAF interaction assays with INHAT and RAR, bacu-
lovirus expressed Flag-p300 and Flag-PCAF were separately puri-of the peptides was facilitated by database correlation with the algo-
rithm SEQUEST and programs developed in the Harvard Microchemis- fied using anti-Flag M2-antibody affinity beads (Sigma) and incu-
bated with radiolabeled INHAT subunits or RAR 1 1 mM all transtry and Proteomics Facility ( Eng et al., 1994; Chittum et al., 1998).
The identified peptides of p48, p44, p32, and p31 are as follows. retinoic acid (ATRA) (Cayman Chemicals). Beads were washed ex-
tensively and bound proteins separated by SDS-PAGE and analyzedp48 (TAF-I a/gi 2136258): 5RQSPLPPQKK14, 14KKPRPPPALGPEET
SASAGLPK35, 40EQQEAIEHIDEVQNEIDRLNEQASEEILKVEQK72, 84RSE by phosphorimager. Both Flag-p300 and Flag-PCAF bound to affin-
ity beads used in this assay display expected activity in HAT assays.LIAK90, 123VEVTEFEDIK132, 137IDFYFDENPYFENK150, 155EFHLNESGDP
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Chromatin Immunoprecipitation (ChIP) References
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